Study of stem cell transplant and CD7-CART for T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have T-cell lymphoma or T-lymphoblastic leukemia that has a protein called CD7 on the cells.
- You must not have had a stem cell transplant before.
- Your heart, lungs, liver, and kidneys must be working well enough (your doctor will check this).
- Women who could get pregnant must have a negative pregnancy test and use birth control for 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
This trial tests a new treatment that uses your own immune cells, modified to attack cancer cells, followed by a stem cell transplant to help rebuild your immune system. It is for people with a type of T-cell lymphoma that has not responded to standard treatments.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
Hear when a new T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.